Poisons (Amendment) Rules 2002 - Singapore Statutes Online

No. S 473

Poisons Act

Poisons (Amendment) Rules 2002

In exercise of the powers conferred by section 20(1) of the Poisons Act, the Minister for Health hereby makes the following Rules:

Citation and commencement

1. These Rules may be cited as the Poisons (Amendment) Rules 2002 and shall come into operation on 16 September 2002.

Amendment of First Schedule

2. The First Schedule to the Poisons Rules (R 1) is amended —

(a)

by inserting, immediately below the item “Almitrine; its salts”, the following item:

“Alosetron; its salts”;

(b)

by inserting, immediately below the item “Atorvastatin; its salts”, the following item:

“Atosiban; its salts”;

(c)

by deleting the item “Bupivacaine; its salts” and substituting the following item:

“Bupivacaine; its salts; its isomers; their salts”;

(d)

by inserting, immediately below the item “Calabar bean; alkaloids of; their quarternary compounds; their salts”, the following item:

“Calcipotriol”;

(e)

by inserting, immediately below the item “Carvedilol”, the following item:

“Caspofungin; its salts”;

(f)

by deleting the item “Cetirizine; its salts” and substituting the following items:

“Cetirizine; its salts; its isomers; their salts

Cetrorelix; its salts”;

(g)

by inserting, immediately below the item “Clindamycin; its salts; its esters; their salts”, the following item:

“Clioquinol”;

(h)

by inserting, immediately below the item “Daclizumab”, the following item:

“Dalfopristin”;

(i)

by inserting, immediately below the item “Debrisoquine; its salts”, the following items:

“Deferiprone

Deferoxamine; its salts”;

(j)

by inserting, immediately below the item “Doxepin; its salts”, the following item:

“Doxofylline; its salts”;

(k)

by inserting, immediately below the item “Droperidol”, the following item:

“Drosperinone”;

(l)

by inserting, immediately below the item “Efavirenz”, the following item:

“Eletriptan; its salts”;

(m)

by inserting, immediately below the item “Etafedrine; its salts”, the following item:

“Etanercept”;

(n)

by inserting, immediately below the item “Etonitazene; its salts”, the following item:

“Etonogestrel”;

(o)

by inserting, immediately below the item “Etoposide; its salts”, the following item:

“Etoricoxib”;

(p)

by inserting, immediately below the item “Feprazone”, the following item:

“Fexofenadine; its salts; its esters; their salts”;

(q)

by inserting, immediately below the item “Follicle stimulating hormone (FSH)”, the following item:

“Fondaparinux; its salts”;

(r)

by inserting, immediately below the item “Gadopentetic acid; its salts”, the following item:

“Gadoversetamide”;

(s)

by inserting, immediately below the item “Ganciclovir; its salts”, the following items:

“Ganirelix; its salts

Gatifloxacin; its salts; its isomers; its esters; their salts”;

(t)

by inserting, immediately below the item “Gemfibrozil; its salts; its esters and salts of such esters”, the following item:

“Gemtuzumab Ozogamicin”;

(u)

by inserting, immediately below the item “Glutethimide; its salts”, the following item:

“Glyceryl trinitrate”;

(v)

by inserting, immediately below the item “Ifosfamide”, the following item:

“Imatinib; its salts”;

(w)

by inserting, immediately below the item “Indomethacin; its salts”, the following item:

“Insulins”;

(x)

by inserting, immediately below the item “Itraconazole”, the following item:

“Ivermectin”;

(y)

by inserting, immediately below the item “Lepirudin”, the following item:

“Lercanidipine; its salts”;

(z)

by inserting, immediately below the item “Levamphetamine; its salts”, the following item:

“Levetiracetam; its salts; its isomers; their salts”;

(za)

by deleting the item “Levophanol; its salts; its esters and ethers; their salts” and substituting the following items:

“Levorphanol; its salts; its esters and ethers; their salts

Levosimendan”;

(zb)

by inserting, immediately below the item “Loperamide; its salts”, the following item:

“Lopinavir”;

(zc)

by deleting the item “Luteinising hormone” and substituting the following items:

“Lumefantrine; its salts; its isomers; their salts

Luteinising hormones”;

(zd)

by inserting, immediately below the item “Midazolam; its salts”, the following item:

“Midodrine; its salts; its isomers; their salts”;

(ze)

by inserting, immediately below the item “Natamycin; its salts; its esters; their salts”, the following item:

“Nateglinide”;

(zf)

by inserting, immediately below the item “Nealbarbitone”, the following item:

“Nebivolol; its salts”;

(zg)

by deleting the item “Omeprazole; its salts” and substituting the following item:

“Omeprazole; its salts; its isomers; their salts”;

(zh)

by inserting, immediately below the item “Orthocaine; its salts”, the following item:

“Oseltamivir; its salts”;

(zi)

by inserting, immediately below the item “Pargyline; its salts”, the following item:

“Paricalcitol”;

(zj)

by inserting, immediately below the item “Piperidolate; its salts”, the following item:

“Piper methysticum (kava-kava), the active constituents of; kava pyrones (kavalactones); their quarternary compounds; their salts”;

(zk)

by deleting the item “Pyrantel; its salts”;

(zl)

by inserting, immediately below the item “Quinine; its quarternary compounds, their salts”, the following item:

“Quinupristin”;

(zm)

by inserting, immediately below the item “Racemorphan; its salts; its esters and ethers; their salts”, the following item:

“Radioactive iodine, salts of; when contained in preparations intended for the treatment of human ailments”;

(zn)

by inserting, immediately below the item “Ranitidine; its salts”, the following item:

“Rasburicase”;

(zo)

by inserting, immediately below the item “Reserpine”, the following item:

“Residronic acid; its salts”;

(zp)

by inserting, immediately below the item “Sevoflurane”, the following item:

“Sibutramine; its salts”;

(zq)

by inserting, immediately below the item “Simvastatin”, the following item:

“Sirolimus”;

(zr)

by inserting, immediately below the item “Streptozocin”, the following item:

“Strontium [⁸⁹Sr], salts of; when contained in preparations intended for the treatment of human ailments”;

(zs)

by inserting, immediately below the item “Teicoplanin”, the following item:

“Telithromycin; its salts”;

(zt)

by inserting, immediately below the item “Temazepam”, the following items:

“Temozolomide

Tenecteplase”;

(zu)

by inserting, immediately below the item “Thyroxine; its salts”, the following item:

“Tiagabine; its salts; its esters; their salts”;

(zv)

by inserting, immediately below the item “Tioconazole”, the following item:

“Tiotropium; its salts”;

(zw)

by inserting, immediately below the item “Trastuzumab”, the following item:

“Travoprost”;

(zx)

by deleting the item “Ubidecarenone (Co-enzyme Q10)”;

(zy)

by inserting, immediately below the item “Urapidil; its salts”, the following item:

“Urea, when contained in preparations intended for treatment of human ailments and containing more than 10% of urea”;

(zz)

by inserting, immediately below the item “Veratrum; alkaloids of; its quarternary compounds, their salts, except substances containing less than 1% of the alkaloids of veratrum”, the following item:

“Verteporfin; its salts; its isomers; their salts”; and

by inserting, immediately below the item “Zipeprol; its salts”, the following items:

“Ziprasidone; its salts

Zolendronic acid; its salts”;

Amendment of Second Schedule

3. The Second Schedule to the Poisons Rules is amended —

(a)

by inserting, immediately below the item “Chloroform”, the following item:

“Clotrimazole

Preparations intended for dermatological uses, containing not more than 1% of clotrimazole.”;

(b)

by inserting immediately below the item “Creosote obtained from wood”, the following item:

“Diclofenac diethylammonium

Preparations intended for external application only, and containing diclofenac diethylammonium salt equivalent to not more than 1% of diclofenac sodium.”;

(c)

by inserting, immediately below the item “Disulfiram”, the following item:

“Econazole; its salts

Preparations intended for dermatological uses, containing not more than 1% of econazole calculated as its free base.”;

(d)

by inserting, immediately below the item “Hydroxyquinoline; its salts; its derivatives; their salts”, the following item:

“Ketoconazole; its salts

Preparations intended for dermatological uses, containing not more than 1% of ketoconazole calculated as its free base.”;

(e)

by inserting, immediately below the item “Mescaline; its salts”, the following item:

“Miconazole; its salts

Preparations intended for dermatological uses, containing not more than 2% of miconazole calculated as its free base.”; and

(f)

by deleting the item “Selenium sulphide” and its entries and substituting the following item:

“Selenium sulphide

External preparations containing not more than 2.5% of selenium sulphide.”.

Amendment of Third Schedule

4. The Third Schedule to the Poisons Rules is amended —

(a)

by deleting the item “Acyclovir” and substituting the following item:

“Acyclovir; except in dermatological preparations containing not more than 5% of acyclovir”;

(b)

by inserting, immediately below the item “Almitrine; its salts”, the following item:

“Alosetron; its salts”;

(c)

by inserting, immediately below the item “Atorvastatin; its salts”, the following item:

“Atosiban; its salts”;

(d)

by deleting the item “Beclomethasone; its salts; its esters; theirs salts” and substituting the following item:

“Beclomethasone; its salts; its esters; their salts; except in nasal sprays containing not more than 0.05% of beclomethasone, calculated as its free base”;

(e)

by deleting the item “Budesonide; its salts” and substituting the following item:

“Budesonide; its salts; except in nasal sprays containing not more than 0.2% of budesonide”;

(f)

by inserting, immediately below the item “Cabimicina; its salts; its esters; their salts”, the following item:

“Calcipotriol”;

(g)

by inserting, immediately below the item “Carvedilol”, the following item:

“Caspofungin; its salts”;

(h)

by inserting, immediately below the item “Cerivastatin; its salts”, the following item:

“Cetrorelix; its salts”;

(i)

by deleting the item “Cimetidine; its salts” and substituting the following item:

“Cimetidine; its salts; except oral preparations containing not more than 100mg in solid dosage form, or 100mg/5ml in liquid dosage form, of cimetidine, calculated as its free base”;

(j)

by inserting, immediately below the item “Clindamycin; its salts; its esters; their salts”, the following item:

“Clioquinol”;

(k)

by inserting, immediately below the item “Daclizumab”, the following item:

“Dalfopristin”;

(l)

by inserting, immediately below the item “Debrisoquine; its salts”, the following items:

“Deferiprone

Deferoxamine; its salts”;

(m)

by deleting the item “Domperidone” ;

(n)

by inserting, immediately below the item “Doxepin; its salts”, the following item:

“Doxofylline; its salts”;

(o)

by inserting, immediately below the item “Droperidol”, the following item:

“Drosperinone”;

(p)

by inserting, immediately below the item “Efavirenz”, the following item:

“Eletriptan; its salts”;

(q)

by inserting, immediately below the item “Etafedrine; its salts”, the following item:

“Etanercept”;

(r)

by inserting, immediately below the item “Etomidate; its salts”, the following item:

“Etonogestrel”;

(s)

by inserting, immediately below the item “Etoposide; its salts”, the following item:

“Etoricoxib”;

(t)

by deleting the item “Famotidine” and substituting the following item:

“Famotidine; except oral preparations containing not more than 10mg of famotidine calculated as its free base”;

(u)

by inserting, immediately below the item “Feprazone”, the following item:

“Fexofenadine; its salts; its esters; their salts”;

(v)

by inserting, immediately below the item “Follicle stimulating hormone (FSH)”, the following item:

“Fondaparinux; its salts”;

(w)

by inserting, immediately below the item “Gadopentetic acid; its salts”, the following item:

“Gadoversetamide”;

(x)

by inserting, immediately below the item “Ganciclovir; its salts”, the following items:

“Ganirelix; its salts

Gatifloxacin; its salts; its isomers; its esters; their salts”;

(y)

by inserting, immediately below the item “Gemfibrozil; its salts; its esters and salts of such esters”, the following item:

“Gemtuzumab Ozogamicin”;

(z)

by inserting, immediately below the item “Glutethimide; its salts”, the following item:

“Glyceryl trinitrate; except when contained in sublingual preparations or transdermal patches”;

(za)

by inserting, immediately below the item “Hexoestrol; its salts”, the following item:

“Human blood products; except when contained in diagnostic kits”;

(zb)

by deleting the item “Ibuprofen; except when contained in dermatological preparations” and substituting the following item:

“Ibuprofen; except in dermatological preparations, or oral preparations containing not more than 200mg in solid dosage form, or 100mg/5ml in liquid dosage form, of ibuprofen”;

(zc)

by inserting, immediately below the item “Ifosfamide”, the following item:

“Imatinib; its salts”;

(zd)

by inserting, immediately below the item “Itraconazole”, the following item:

“Ivermectin”;

(ze)

by inserting, immediately below the item “Lepirudin”, the following item:

“Lercanidipine; its salts”;

(zf)

by inserting, immediately below the item “Levamphetamine; its salts”, the following item:

“Levetiracetam; its salts; its isomers; their salts”;

(zg)

by inserting, immediately below the item “Levonorgestrel”, the following item:

“Levosimendan”;

(zh)

by inserting, immediately below the item “Lonazolac; its salts”, the following item:

“Lopinavir”;

(zi)

by deleting the item “Luteinising hormone” and substituting the following items:

“Lumefantrine; its salts; its isomers; their salts

Luteinising hormones”;

(zj)

by inserting, immediately below the item “Midazolam; its salts”, the following item:

“Midodrine; its salts; its isomers; their salts”;

(zk)

by deleting the item “Minoxidil; its salts; except in dermatological preparations containing not more than 2% of minoxidil” and substituting the following item:

“Minoxidil; its salts; except when contained in topical preparations”;

(zl)

by inserting, immediately below the item “Natamycin; its salts; its esters; their salts”, the following item:

“Nateglinide”;

(zm)

by inserting, immediately below the item “Nealbarbitone”, the following item:

“Nebivolol; its salts”;

(zn)

by deleting the item “Nicotine; its salts; its quarternary compounds; their salts; except when contained in transdermal patches” and substituting the following item:

“Nicotine; its salts; its quarternary compounds; their salts; except when contained in transdermal patches or inhalers”;

(zo)

by deleting the item “Omeprazole; its salts” and substituting the following item:

“Omeprazole; its salts; its isomers; their salts”;

(zp)

by inserting, immediately below the item “Orphenadrine; its salts”, the following item:

“Oseltamivir; its salts”;

(zq)

by inserting, immediately below the item “Pargyline; its salts”, the following item:

“Paricalcitol”;

(zr)

by deleting the item “Piroxicam” and substituting the following item:

“Piroxicam; except when contained in preparations intended for external application only”;

(zs)

by inserting, immediately below the item “Quinine; its quarternary compounds, their salts”, the following item:

“Quinupristin”;

(zt)

by inserting, immediately below the item “Rabeprazole; its salts; its esters and ethers; their salts”, the following item:

“Radioactive iodine, salts of; when contained in preparations intended for the treatment of human ailments”;

(zu)

by deleting the item “Ranitidine; its salts” and substituting the following items:

“Ranitidine; its salts; except oral preparations containing not more than 75mg in solid dosage form, or 150mg/10ml in liquid dosage form, of ranitidine, calculated as its free base

Rasburicase”;

(zv)

by inserting, immediately below the item “Reserpine”, the following item:

“Residronic acid; its salts”;

(zw)

by inserting, immediately below the item “Sertraline; its salts”, the following item:

“Sibutramine; its salts”;

(zx)

by inserting, immediately below the item “Simvastatin”, the following item:

“Sirolimus”;

(zy)

by deleting the item “Sodium cromoglycate” and substituting the following item:

“Sodium cromoglycate; except ophthalmic or nasal preparations containing not more than 2% of sodium cromoglycate”;

(zz)

by inserting, immediately below the item “Streptozocin”, the following item:

“Strontium [⁸⁹Sr], salts of; when contained in preparations intended for the treatment of human ailments”;

by inserting, immediately below the item “Teicoplanin”, the following item:

“Telithromycin; its salts”;

by inserting, immediately below the item “Temazepam”, the following items:

“Temozolomide

Tenecteplase”;

by deleting the item “Terbinafine; its salts” and substituting the following item:

“Terbinafine; its salts; except dermatological preparations containing not more than 1% of terbinafine, calculated as its free base”;

by inserting, immediately below the item “Thyroxine; its salts”, the following item:

“Tiagabine; its salts; its esters; their salts”;

by inserting, immediately below the item “Tinzaparin; its salts”, the following item:

“Tiotropium; its salts”;

by inserting, immediately below the item “Trastuzumab”, the following item:

“Travoprost”;

by deleting the item “Triamcinolone; its salts” and substituting the following item:

“Triamcinolone; its salts; except preparations containing not more than 0.1% of triamcinolone acetonide in orabase”;

by deleting the item “Ubidecarenone (Co-enzyme Q10)”;

by inserting, immediately below the item “Verapamil; its salts”, the following item:

“Verteporfin; its salts; its isomers; their salts”; and

by inserting, immediately below the item “Zipeprol; its salts”, the following items:

“Ziprasidone; its salts

Zolendronic acid; its salts”.

[G.N. Nos. S 632/98; S 51/99; S 177/99; S 279/99; S 68/2000; S 238/2001]

Made this 5th day of September 2002.

MOSES LEE

Permanent Secretary,
Ministry of Health,
Singapore.

[CPA (PER): 78:01 Vol. 5; AG/LEG/SL/234/2002/1 Vol. 1]

(To be presented to Parliament under section 20(2) of the Poisons Act).

Search within Legislation